ArticleCurrent issues in molecular biology2026
Comparison of a Novel MRNA-Based Breast Cancer Subtyping Assay with PAM50 and Oncotype DX in Estrogen Receptor-Positive/HER2-Negative Breast Cancer: An Exploratory Age-Stratified Retrospective Cohort Study.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunohistochemistry (IHC) of ER, PR, HER2, and Ki67 are established prognostic and predictive markers in breast cancer. Gene expression assays such as PAM50 and Oncotype DX are increasingly used for molecular subtyping and recurrence risk calculation. The APIS Breast Cancer Subtyping Kit (BCSK) quantitatively measures the mRNA expression of these markers (ER, PR, HER2, and Ki67) and includes a novel four-gene BCSK Proliferation Signature (PS) designed for subtype classification and risk stratification. This exploratory retrospective cohort study compares the BCSK with established molecular assays in an age-stratified cohort. We aimed to compare BCSK subtype classification in distinguishing Luminal A versus Luminal B subtypes with IHC and with PAM50. We have also aimed to assess correlations between the BCSK PS and the Oncotype DX Recurrence Score (RS) as well as the PAM50 Risk of Recurrence (ROR) score in patients stratified by age (<65 versus ≥65 years). Formalin-fixed, paraffin-embedded (FFPE) tumor specimens from 59 patients with ER+/HER2- breast cancer (33 < 65 years, 26 ≥ 65 years), diagnosed between 2020 and 2022 at the Cantonal Hospital Baselland and University Hospital Basel, were analyzed using IHC, BCSK, and PAM50 (Prosigna
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.